PULMONARY HYPERTENSION IN PATIENTS WITH SEVERE AORTIC STENOSIS: CLINICAL PROFILE, PROGNOSTIC IMPLICATION AND RESPONSE TO TRANSCATHETER AORTIC IMPLANTATION  by Ben-Dor, Itsik et al.
    
 i2 SUMMIT   
A178.E1662 
JACC March 9, 2010
Volume 55, issue 10A
PULMONARY HYPERTENSION IN PATIENTS WITH SEVERE AORTIC STENOSIS: CLINICAL PROFILE, 
PROGNOSTIC IMPLICATION AND RESPONSE TO TRANSCATHETER AORTIC IMPLANTATION
i2 Oral Contributions
Georgia World Congress Center, Room B308
Sunday, March 14, 2010, 8:12 a.m.-8:24 a.m.
Session Title: Valvular Interventions
Abstract Category: PCI - Valvular; Atrial Fibrillation Therapies
Presentation Number: 2901-06
Authors: Itsik Ben-Dor, Steven A. Goldstein, Augusto D. Pichard, Lowell F. Satler, Rebecca Torguson, Petros Okubagzi, Zhenyi Xue, Yanlin Li, Asmir 
I. Syed, Zuyue Wang, Manuel A. Gonzalez, Michael A. Gaglia, Gabriel Maluenda, Kohei Wakabayashi, Cedric Delhaye, Nicholas N. Hanna, Sara D. 
Collins, William O. Suddath, Kenneth M. Kent, Joseph Lindsay, Ron Waksman, Washington Hospital Center, Washington, DC, DC
Background: The incidence, predictors and prognostic implication of pulmonary hypertension (PH) in patients (pts) with severe aortic stenosis 
(AS) are unclear. We aimed to investigate the impact of transcatheter aortic valve implantation (TAVI) on PH in pts with severe AS.
Methods: We studied 396 pts with severe AS who were referred for TAVI. Pts with mitral stenosis, severe mitral regurgitation/mechanical valve or 
known PH were excluded. The cohort was studied according to the degree of pulmonary pressure (PP): group 1, 124 (31.3%) with PP <40 mmHg, 
group 2, 149 (37.6%) with PP 40-60 mmHg, and group 3, 123 (31.0%) with PP >60 mmHg.
Results: The mean age was lowest in the severe PP group. Pts with severe PP had higher STS/EuroSCORE, creatinine level, CRP level, left atrium 
diameter, lower ejection fraction (EF) and smaller aortic valve area (AVA). The predictors for PH were STS, EuroSCORE, NYHA class, renal failure, lower 
EF and AVA. Multivariable analyses identified AVA as the strongest predictor for PH. In 53 pts who underwent TAVI, there was no significant change in 
PH immediately after the procedure and at 1 year, however in 23 pts with PP >50 mmHg there was a significant decrease in PP during median follow 
up of 13 days ( 64.9± 14.2 vs. 52.1±13.4 mmHg, p<0.001). At 1 year the PP remained low -- 48.2±6.4 mmHg.
Conclusion: Pts with severe AS tend to have high incidences of PH which is associated with high mortality rates. TAVI is an effective treatment for 
these pts and resulted in a significant reduction of PH.
Normal pulmonary pressure
N=124
Mild-moderate pulmonary 
pressure N=149
Severe pulmonary pressure
N=123
P value
Age (years) 81.9±7.7 82.5±8.2 79.7±9.2 0.01
Men, n (%) 57 (46) 69 (46.3) 53 (43.1) 0.8
STS score (%) 9.9±5.8 11.9±5.4 13.2±7.5 <0.001
Logistic Euro score (%) 27.5±20.9 40.7±20.7 48.8±22 <0.001
Creatinine (mg %) 1.2±0.5 1.3±0.6 1.7±1.5 <0.001
CRP (mg/dl) 9.7±16.9 14.3±22.3 25.4±42.4 0.01
Aortic valve area (cm2) 0.74±0.2 0.72±0.15 0.68±0.18 0.03
Ejection fraction (%) 54.1±15.7 49.6±15.9 45.0±18.9 <0.001
Pulmonary vascular resistance (Wood) 2.0±1.5 2.3±2.2 4.0±2.6 <0.001
Left atrium diameter (mm) 4.1±0.68 4.5±0.72 4.7±0.6 <0.001
Mortality, n (%) 23 (18.5) 52 (34.9) 53 (43.1) <0.001
